BofA Securities initiated coverage of Evercore (NYSE:EVR) with a Buy rating and $435 price target, calling it the 'best pure-play among boutique investment banks.' The analyst highlights Evercore's high advisory revenue mix (80% of total), strong M&A expertise, and growth potential from franchise expansion. With M&A activity expected to reach record highs in 2026, the firm is positioned for positive earnings revisions.

ProQR Therapeutics will participate in the 8th Annual Evercore Healthcare Conference, presenting its Axiomer™ RNA editing technology platform that enables targeted single nucleotide changes in RNA to potentially develop new disease treatments.

Madrigal Pharmaceuticals will participate in three upcoming healthcare investor conferences in November and December 2025, presenting live webcasts about their MASH treatment Rezdiffra.

Wall Street analysts predict the S&P 500 could experience significant volatility in 2026, with potential scenarios ranging from a 30% surge to a 30% decline, driven by factors like AI adoption, economic conditions, and potential interest rate changes.

Standard Lithium announced a public offering of 29,885,057 common shares at $4.35 per share, raising $130 million to fund capital expenditures for its lithium projects in Arkansas and Texas.

Sprouts Farmers Market stock has fallen 40% since June, but analysts suggest it may be oversold and poised for a potential rebound ahead of upcoming earnings, citing strong historical performance and technical indicators.

Western Digital has expanded its System Integration and Test (SIT) Lab to a 25,600-square-foot facility, aimed at accelerating customer adoption and addressing growing AI storage demands through high-capacity hard disk drives (HDDs).

Dianthus Therapeutics plans to raise $150 million through a public offering of common stock or pre-funded warrants, with potential additional $22.5 million from underwriters. Proceeds will support preclinical and clinical development activities.

Zacks Research downgraded Amazon from Strong Buy to Hold, marking a rare shift in analyst sentiment. Despite the downgrade, most analysts remain bullish, with price targets ranging from $280-$300, and the stock continues to show strong momentum.

Mineralys Therapeutics has priced a public offering of 9,803,921 shares at $25.50 per share, expecting to raise approximately $250 million to fund clinical development and corporate activities.

Centrus Energy's stock rose 12.3% after signing a memorandum of understanding with Korea Hydro & Nuclear Power to explore uranium enrichment facility expansion, with Evercore ISI recognizing the company as an emerging player in the U.S. nuclear energy industry.

Amazon's stock shows potential for a rally after a bullish MACD crossover, with analysts maintaining a positive outlook and price targets suggesting over 30% upside potential.